BIIB · Biogen Inc. · Documents

Biogen reported Q3 2026 revenue of $2.8 billion, up 11% year-over-year, and raised the lower end of 2026 non-GAAP diluted EPS guidance to between $12.20 and $13.00. It expects at least $250 million of run rate synergies by the end of 2027.

Biogen completed its Apellis acquisition on May 14, 2026, adding SYFOVRE and EMPAVELI; third-quarter total revenue rose $269.4 million, or 10.6%, while total cost and expense rose $835.7 million, or 42.3%.

Biogen reported third-quarter 2026 revenue of $2.8 billion, up 11% year-over-year, GAAP diluted EPS of $(0.14), and Non-GAAP diluted EPS of $2.62. It raised the lower end of full-year Non-GAAP diluted EPS guidance to $12.20 to $13.00 from $12.00 to $13.00.